Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.
You may also be interested in...
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
Pfizer's block against Teva's generic Lipitor in the U.K. will remain in place until a full trial later this year; pharmacies caught between the warring factions.
Pfizer wins temporary injunction on Teva's U.K launch of generic atorvastatin; hearing scheduled for July.